3Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab, 2004,89:1704-1711. 被引量：1
4Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med, 2003,349: 2023-2033. 被引量：1
5Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab,2001,86:3809-3814. 被引量：1
6Mangupli R, Lisette A, Ivett C, et al. Improvement of acromegaly after octreotide LAR treatment. Pituitary, 2003,6: 29-34. 被引量：1
7Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab, 2003, 88: 3090-3098. 被引量：1
8Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab, 2003,88: 5258-5265. 被引量：1
9Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab,2004,89:1577-1585. 被引量：1
10Parkinson C, Kassem M, Heickendorff L, et al. Pegvisomant-induced serum insulin-like growth factor-Ⅰ normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab, 2003,88: 5650-5655. 被引量：1
